Fig 1: Enhanced Raf/MEK/ERK signaling axis accounts for triggering mitophagy and decreased lipid accumulation upon Rab1A knockdown (A) Flowchart scheme for 4D label‐free quantitative proteomic and phosphoproteomic analysis using shControl and shRab1A AML12 cells treated with 50 µm PA‐BSA for 48 h. (B) Top 10 enriched KEGG pathways of PA‐BSA‐treated Rab1A knockdown (KD) versus shControl cells, with differentially abundant proteins identified and analyzed by phosphoproteomic analysis. The lowest p‐value was selected for this analysis. (C) Differential abundance of phosphopeptides generated from (A) was shown in a bubble plot of potential signaling pathways. The size and color of each bubble represent the number of proteins in each pathway and the p‐value, respectively. (D) KEGG pathway highlighting the changed phosphorylated proteins in the MAPK signaling pathway extracted from both two cell types. Down‐regulated proteins are shown in green, up‐regulated in red color and unchanged in cyan. (E) Differentially expressed phosphopeptides between the two groups are shown by a volcano plot. X‐axis indicates the fold change (logarithmic conversion based on 2), and the Y‐axis indicates the P‐value (logarithmic conversion based on 10). Red dots represent up‐regulated phosphopeptides with significance, while blue dots indicate down‐regulated phosphopeptides with significance, and grey dots show the phosphopeptides without significance. (F) The intensities of phosphorylated A‐Raf and Raf‐1 are shown in both groups. Results are presented as mean ± SEM (n = 3), ****p < 0.0001, unpaired Student's t‐test. (G) Immunoblot analysis of components of the Raf‐1/MEK/ERK signaling pathway in shControl and shRab1A cells combined w/ or w/o PA‐BSA treatment. (H) Immunoblot analysis of phosphorylated ERK1/2 and PINK1 in Scramble and shRab1A mouse liver tissues. (I) Evaluation of mitophagy upon treatment with U0126 by immunostaining in shControl and shRab1A cells on PA‐BSA. White speckles indicated by arrows show occurrences of mitophagy. Scale bar, 20 µm.
Fig 2: Boosting mitophagy via the ERK1/2/PINK1 signaling axis lessens lipid accumulation and ameliorates WD‐induced hepatic dysfunction. (A,B) Representative immunoblots performed with shControl and shRab1A cells treated with Urolithin A and C16‐PAF. The cells were treated for 24 h at the indicated concentrations. Phosphorylated ERK1/2 and mitophagy markers such as p‐PINK1 (S228), p‐Parkin (S65), and LC3B were detected. (C) Evaluation of mitophagy upon treatment with Urolithin A and C16‐PAF by immunostaining in shControl cells on PA‐BSA. White speckles indicate occurrences of mitophagy. Scale bars: 25 and 10 µm. (D) Experimental design for assessing the effects of two compounds (Urolithin A and C16‐PAF) in WD‐fed mice (for WD + Vehicle, WD + Urolithin A, WD + C16‐PAF, n = 10; for Normal chow, n = 5). (E) Weekly body weight of mice administered vehicle, Urolithin A, and C16‐PAF on diet, and normal chow‐fed mice. All results are presented as mean ± SEM (for WD + Vehicle, WD + Urolithin A, WD + C16‐PAF, n = 10; for Normal chow, n = 5). ***p < 0.001, ****p < 0.0001, analyzed by two‐way analysis of variance (ANOVA) followed by Šidák's multiple comparisons test. (F,G) GTT (F) and ITT (G) of 4 groups of mice after 16 weeks of treatment. All results are presented as mean ± SEM (GTT assay, WD + Vehicle and WD + Urolithin A groups n = 10, WD + C16‐PAF, n = 9; for Normal chow n = 5; ITT assay, WD + Vehicle, WD + Urolithin A, WD + C16‐PAF, n = 10; for Normal chow n = 5). *p < 0.05, **p < 0.01, analyzed by two‐way analysis of variance (ANOVA) followed by Šidák's multiple comparisons test. (H) Quantification of triglyceride levels in sera from 4 groups of mice. Results are presented as mean ± SEM (for WD + Vehicle, WD + Urolithin A, WD + C16‐PAF, n = 8; for Normal chow, n = 5). *p < 0.05, ** p < 0.01, unpaired Student's t‐test for two groups. (I,J) Quantification of ALT and AST in sera from 4 groups of mice. Results are presented as mean ± SEM (n = 7 in WD + Vehicle and WD + Urolithin A groups, n = 8 in WD + C16‐PAF, n = 5 in Normal chow for ALT) (n = 7 in WD + Vehicle, n = 6 in WD + Urolithin A, n = 8 in WD + C16‐PAF, n = 4 in Normal chow for AST). **p < 0.01, ***p < 0.001, ****p < 0.0001, unpaired Student's t‐test. (K) Multiple evaluations of hepatic steatosis with liver tissues from 4 groups. The overview of dissected livers (left panel) and supernatants of respective lysates (middle panel) and H&E staining analysis (right panel). The cloudier the supernatants, the more triglycerides the livers contain. Scale bar, 200 µm. (L) Pathological analysis performed with liver sections from 4 groups of mice. Severity of hepatic steatosis is indicated by NAFLD Activity Score (NAS). All results are presented as mean ± SD (for WD + Vehicle, WD + Urolithin A, WD + C16‐PAF, n = 10; for Normal chow, n = 5). **p < 0.01, ***p <0.001, unpaired Student's t‐test.
Fig 3: ERK1/2 directly regulates PINK1's phosphorylation via interaction. (A) Immunoblot analysis of phosphorylation of ERK1/2 and PINK1 upon treatment with gradient concentrations of U0126 and Urolithin A. (B) Endogenous immunoprecipitation (IP) was performed using ERK1/2 antibodies in AML12 cells to verify the interaction between ERK1/2 and PINK1. (C) Exogenous IP was conducted using Flag beads. Flag‐ERK1/2 and Myc‐PINK1 were co‐transfected at an equimolar ratio in 293T cells. (D) Representative confocal images show the colocalization of endogenous ERK1/2 and PINK1. Fluorescence intensity was quantified by ImageJ to show the colocalization of the two proteins. Scale bar, 10 µm. (E) Interaction between ERK1‐PINK1 and ERK2‐PINK1 was confirmed by proximity ligation assay (PLA) exogenously. Green fluorescent dots indicate the closeness of ERK1‐PINK1 and ERK2‐PINK1. Scale bar: 10 µm. (F,G) AlphaFold3‐predicted interaction between ERK1/2 and PINK1. Structural modeling of the ERK1/2–PINK1 complex with key interface residues highlighted. Binding energy and interface area are indicated. (H) Schematic illustration of functional modules of PINK1 and its truncated mutants. (I,J) Physical interaction regions between ERK1/2 and PINK1 were characterized by IP. Myc‐tagged truncated PINK1 mutants were co‐transfected with Flag‐ERK1 in (I) and Flag‐ERK2 in (J) and then subjected to IP using Flag beads. Inputs of PINK1 and its mutants were marked by asterisks.
Fig 4: Elevated Rab1A correlates with attenuated activities of Raf‐1/ERK1/2/PINK1 in patients with MASLD (A) Analysis of Rab1A expression in human normal (NAS score 0–3) and MASLD (NAS score 4–7) liver tissues. All results are presented as mean ± SEM (n = 38). ****p < 0.0001, unpaired Student's t‐test. (B,C) Analyses of activated Raf‐1 and ERK1/2 by IHC staining with phospho‐specific antibodies against Raf‐1 (S338) and ERK1/2 (T202/Y204) in human normal and MASLD liver tissues. All results are presented as mean ± SEM (n = 38). ****p < 0.0001, unpaired Student's t‐test. (D) Trends of MASLD activity score (NAS), Rab1A expression, and activation of Raf‐1/ERK1/2/PINK1 analyzed by H&E staining and IHC with the indicated antibodies (Patient cohort = 38, as shown in Table S3). Representative images are shown here. Scale bar, 200 µm. (E) Examination of the negative correlation between Rab1A and activation of Raf‐1/ERK1/2 analyzed by IF staining with respective antibodies in high‐, medium‐, and low‐NAS‐score liver tissues. Representative images are shown here. Arrows indicate lipid droplets. Scale bars: 100 and 25 µm. (F) Concomitant activation of ERK1/2 and PINK1 was determined by IF staining using specific antibodies in high‐, medium‐, and low‐NAS‐score liver tissues. Scale bars: 50 and 25 µm. (G) Correlation plot showing Rab1A and p‐Raf‐1(S338) IHC staining (arbitrary units). Analyzed by a Pearson correlation test, the coefficient of correlation (r‐value) and the p‐value (P) are indicated, R 2: 0.6154. (H) Analyses of Rab1A expression in human normal and MASLD liver tissues using datasets GSE130970 (n = 78), GSE225740 (n = 93), and GSE167523 (n = 98) from the GEO database. Analyzed using the Wilcoxon test. p‐values (P) are indicated. (I) A working model depicting the role of Rab1A in mitophagy, DNL, and lipid accumulation in the liver. Rab1A constrains the activation of the Raf‐1/MEK/ERK1/2 cascade, which in turn inhibits mitophagy by decreasing p‐PINK1 (S228, T257) and p‐Parkin (S65). Overactivation of ERK1/2 by knocking out Rab1A or employing compounds (Urolithin A/C16‐PAF) causes excessive mitophagy. Enhanced mitophagy ultimately leads to decreased acetyl‐CoA, limiting substrate availability for de novo lipogenesis. On the other hand, mitophagy preserves and enhances the function of the remaining mitochondria, increasing FAO activity and reducing ROS levels, which together attenuate lipid accumulation and ameliorate MASLD pathology.
Supplier Page from Sino Biological, Inc. for Mouse PINK1 Gene ORF cDNA clone expression plasmid, C-Myc tag